HCV Advocate LogoHCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
Community  & Support
Support Groups
Events
Clinical Trials
Resource Library
About Hcsp
 
 
Clinical Trials

Hepatitis C Clinical Trials

Learn the basics of clinical trials in hepatitis C and find out about clinical trials that you may be eligible for.

This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.

 

PDF How to Evaluate a Clinical Trial July 09

PDF Making Sense of Hepatitis C Research and Medical Literature

Guide to Understanding Clinical Trials and Medical Research in Hepatitis C

ClinicalTrials.gov
Provides regularly updated information about federally and privately supported clinical research in human volunteers.

Centerwatch
Centerwatch list of hepatitis C clinical trials by state


Clinical Trials - Current


We are recruiting patients for the following clinical tirals at Rush Univerity Hepatology:

1. Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
A study to develop observational clinical experience with the use of entecavir in patients who are either of Black/African-American race or of Hispanic ethnicity.

2. Study of TYZEKA in subjects of Black/African American or Hispanic/Latino origin with compensated chronic hepatitis B virus infection.

3. A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy, Safety and Tolerability of AST-120 (Spherical Carbon Adsorbent) for 8 Weeks in the Treatment of Mild Hepatic Encephalopathy

4. Randomised, Placebo-controlled, Multi-centre Study to Assess the Efficacy and Safety of Eltrombopag in Thrombocytopenic Subjects With Hepatitis C Virus (HCV) Infection Who Are Otherwise Eligible to Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin)

 

Contact:

Doris Yadav RN, BS
Senior Research Coordinator
Office: 312-563-3919
Fax: (312) 563-3920
Rush University Medical Center
1725 West Harrison Street
Suite 158 Professional Building
Chicago, Illinois 60612



HEAT Study: Hepatocellular Carcinoma of RFA and ThermoDox® Now Enrolling Recently Diagnosed HCC Patients in Clinical Trials

Celsion Corporation is an oncology drug development company which develops targeted chemotherapeutic treatments based on a unique heat-activated liposomal technology. Celsion is currently enrolling patients in a global Phase III clinical trial – the HEAT Study – which is designed to demonstrate the safety and efficacy of ThermoDox® in hepatocellular carcinoma (HCC) patients.

The HEAT study involves an investigational anti-cancer drug, called ThermoDox®, used in combination with an approved medical device for radiofrequency ablation (RFA) in the liver.

The study will be the largest investigation of RFA in HCC and will involve approximately 600 patients in over 40 research institutions in seven countries and regions.

ThermoDox is designed as a heat-activated liposomal technology that is administered intravenously. When used in combination with RFA to ablate tumors high concentrations of doxorubicin is released directly to the tumor and the surrounding liver tissue. The primary endpoint of the trial is progression-free survival. Details regarding the HEAT Study can be found here.

For more information, contact:
Jeannette Tighe, Principal
MedAdvisoryllc
7 Glenn Road, N. Easton, MA 02356
jtighe@medadvisory.net
508.297.2439



Clinical trial to test HuMax-HepC in people with a chronic hepatitis C infection

The purpose of the study is to determine the safety and tolerability of HuMax-HepC, to be given alone, in people with a chronic hepatitis C infection who have not had a sufficient response to other approved treatments of hepatitis C. Study drug and study procedures will be made available to you at no cost.

Contact:
Marjorie Small,
Research Coordinator
Biomedical Research Alliance of New York Mount Sinai Medical Center
Division of Liver Diseases
One Gustave L. Levy Place Box 1104
New York, NY 10029
Telephone: 212-241-1424
Email: Marjorie.small@mountsinai.org



A Study of Bavituximab (Chimeric Anti-Phosphtidylserine Monoclonal Antibody) in Co-Infected HCV and HIV patients

This study is currently recruiting patients (March 2008)

Sponsored by: Peregrine Pharmaceuticals.

Patients must be 18 years or older. Must be off antiretroviral medications or willing to interrupt ARV for 4 weeks prior to and 4 months during study. Must have CD-4 count greater than 300 cells/mm3.

Contact Information: Dr. Jorge E. Rodriguez Newport Beach, CA 92663 Laurie Riney, RN 949-574-2598


Investigational Drug: Principle Investigator, Dr. Mark S. Sulkowski

Looking for Men aged 18 to 50 with hepatitis C to take part in a research study of an investigational drug.

Involves one 36 hour inpatient stay at Johns Hopkins and 14 outpatient visits. Study will last 7 weeks.

You can earn up to $1325.00 for participating.

Please call:
Heather Thomas
Johns Hopkins University
(410) 614 - 6089


A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C

This study is currently recruiting patients (May 2007).

Sponsored by: Vertex Pharmaceuticals

ClinicalTrials.gov Identifier: NCT00420784

Purpose The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with peginterferon alfa-2a (Pegasys®), and ribavirin (Copegus®) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.

Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00420784 Central Call Center 877-634-VRTX medicalinfo@vrtx.com
Outside US Call Center 617-444-6777


Rituximab (Anti-CD20) for the Treatment of Hepatitis C Associated Cryoglobulinemic Vasculitis

The NIH is currently enrolling patients with Hepatitis C associated cryoglobulinemic vasculitis in a research study which takes place at the NIH Clinical Center in Bethesda, MD.

Patients between 18 and 75 years of age with hepatitis C and signs and symptoms of cryoglobulinemic vasculitis may be eligible for this study. They must have failed, or been unable to tolerate, treatment with IFN-a and ribavirin. Candidates will be screened with a history and physical examination, electrocardiogram (ECG), blood and urine tests, 24-hour urine collection and chest X-ray, if clinically indicated.

For more information click here


Latino, Genotype 1: Treatment Naive Only
University Medical Center-Fresno
MUHAMMAD Y. SHEIKH, M.D. 559-459-4042


UC Davis Medical Center
Lorenzo Rossaro, MD 916-734-2911


Transplant Study For People With HIV Infection
A study to evaluate the safety and efficacy of Kidney and liver transplants in a select population of HIV infected individuals is currently in progress at 17+ transplant centers across the country.

Click here for more information


Clinical Trial for Children/Teens with Hepatitis C
One group will be treated with only pegylated interferon, and the second group will be treated with a combination of pegylated interferon and ribavirin

For more information about enrolling in this trial click here


Study: Neurocognitive Effects of HCV, HIV and Drug Use

UCSD HIV Neurobehavioral Research Center
San Diego, CA 92103

The primary objective of this study is to determine the effects of drug use, HCV infection, and HIV infection on neuropsychological performances, including skills of thinking, memory, attention, and concentration.

Inclusion criteria include: 1) Adults between the ages of 18-60, 2) HIV+ and HIV- adults with known or suspected Hepatitis C infection, and 3) no history of interferon treatment.

Evaluation procedures include a one-day full assessment of: interviews & testing, a medical examination, and fluid sampling. For completing this assessment, you will be compensated.

Contact Information:
Teresa Oyos
Study Recruiter
toyos@ucsd.edu
619.543.5016

 

Clinical Trials - General

  • Schering-Plough
    SCH 50304 Plus Peg-Intron, With and Without Added Ribavirin, in Patients with Chronic Hepatitis C, Genotype 1, who did not respond to peginterferon alfa plus ribavirin.
    Click here for more information.

back to top



Clinical Trials - By Area

Northern California

  • Oakland, CA
    East Bay Liver Clinic
    400-30th St., Ste 200
    Oakland, CA 94609
    Contact: Grant Young - (510) 208-7777

  • Palo Alto, CA
    Stanford University Hospital
    Stanford Liver Research Clinic
    (650) 724-7057

  • San Mateo, CA
    Clinical Trials and Research
    San Mateo Medical Center
    222 W. 39th Avenue
    San Mateo, CA 94403
    Phone: (650) 573-2408
    Fax: (650) 571-7802

back to top

San Francisco, CA

  • University of California, San Francisco
    Clinical Trials
    Norah Terrault, MD
    (415) 353-2409

  • San Francisco VA Medical Center
    Sally George, RN, BSN, CRC
    San Francisco VA Medical Center
    GI Research, 111B
    4150 Clement Street
    San Francisco, CA 94121
    Phone:  (415) 221-4810 x3716
    Fax:  (415) 750-2105
    E-mail:  Sally.George2@va.gov  

  • California Pacific Medical Center
    Allison Gilchrist, RN, MPH
    Work #:(415)600-1768
    Email: GilchrA@sutterhealth.org

    Anna von Bakonyi, LVN, CCRC
    Work #: 415 600-1107
    Email: vonbaka@sutterhealth.org

    Hepatology Research
    Department of Transplantation
    California Pacific Medical Center
    2324 Sacramento Street
    San Francisco, CA 94115
    Fax #: (415)600-1108

  • San Francisco General
    Claudia Ayala (415) 206-3725

back to top

San Rafael, CA

  • Dr. John J. Jolley
    Contact: Lynn Jolley
    Monday, Tuesday, & Wednesday
    (415) 257-3030

back to top


Sacramento

  • Dr. Gish / Leslie Davison (916) 443-0534

  • Dr. Pimstone, UCD Medical Ctr (916) 734-1557

  • University of California, Davis Medical Center
    Dr. Lorenzo Rossaro (916) 734-8696

back to top

Southern California

Irvine, CA

  • UC Irvine Medical Center
    Dr. John Hoefs, Barbara Walker, RN
    (714) 456-7821

back to top

Long Beach, CA

  • VA Medical Center Long Beach
    Dr. Timothy Morgan, Aliya Asghar, CRC
    (562) 826-5212

back to top

Los Angeles, CA

  • USC Hepatitis Research Clinic
    Dr. Karen Lindsay, Susan Milstein, RN
    (323) 442-5550

  • Cedars-Sinai Comprehensive Transplant Center
    Dr. Fred Poordad, Principal Investigator
    8631 W. Third St., Suite #430
    E Los Angeles, CA 90048
    Office: (310) 423-2743 or (310) 423-9545
    Fax: (310) 423-0584

back to top

Newport Beach , CA

  • Jorge E. Rodriguez, MD Principal Investigator
    496 Old Newport Blvd., Suite 4
    Newport Beach, CA 92663
    Office: 949-646-1111
    Research: 949-574-2598
    Fax: 949-646-6972

back to top

Santa Barbara

  • Santa Barbara/Ventura Counties
    Dr. Kip Lyche
    (805) 641-6525
    (415) 353-0800

back to top

San Diego

  • Scripps Clinic
    Helen Broussard (858) 652-5419

  • UCSD Medical Center
    Petrea (619) 543-3599

  • San Diego Medical Associates Research Group
    Dr. Michael Bennett
    (858) 277-5678

back to top


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

Hepatitis C Support Project

© 2009 Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets
Drug Pipeline